Phased-Array Ultrasound Transducer

Dozens of tiny crystals vibrate in precise sequence, bending a beam of sound like a searchlight — without moving a single part.

In imaging mode the array pulses ultrasound into tissue and listens for the echoes that bounce back from density boundaries — vessel walls, organ edges, moving blood — and assembles those echoes into a real-time cross-sectional image. In high-intensity focused ultrasound (HIFU) therapy mode the same principle concentrates kilowatt-peak acoustic energy into a focal spot roughly 1 mm wide by 9 mm long, raising tissue temperature above 60 °C in seconds to destroy tumours without a scalpel.

Each element is a strip of piezoelectric ceramic (typically lead zirconate titanate, PZT, or a PZT-polymer 1–3 composite) that contracts and expands when voltage is applied. A programmable beamformer applies nanosecond-precision time delays — shortest at the centre, longest at the edges — so that the wavefronts from all elements converge at exactly the intended focal depth and steering angle. Because sound travels ~1540 m/s in soft tissue, a 4 ns delay resolution (as in Verasonics Vantage hardware) corresponds to position accuracy finer than 6 µm. On receive, the same delay-and-sum logic coherently adds echoes from each element, sharpening lateral resolution. Typical clinical probes carry 64–192 elements pitched at roughly half a wavelength (~0.15–0.3 mm at 3–5 MHz) to suppress grating lobes while steering up to ±45° off boresight.

In plain terms

Imagine a row of people clapping in turn, one after another, very quickly. The sound waves from their claps add up and travel in a direction nobody is actually facing. Change who claps first and the sound tilts the other way — no one had to move, only the timing changed. That is exactly how a phased-array probe steers a beam of ultrasound through your body.

Also called: PA probe, sector phased array, HIFU array, beamforming transducer.

Why it matters

Where it lives

Key numbers

Surprising facts

Open questions

A short history

Jan Somer at the University of Limburg described phased-array ultrasound scanning in 1968, but the technology remained largely confidential, adapted from wartime sonar research. The first clinically demonstrated real-time phased-array echocardiography system was built by Fredrick Thurstone and Olaf von Ramm at Duke University; their 24-element prototype producing 20-frame-per-second cardiac images was published in 1974–1976 and launched the era of portable cardiac ultrasound. The therapeutic branch of the field traces to Lynn and Putnam, who showed focused ultrasound could produce discrete brain lesions in animals as early as 1942. InSightec's ExAblate 2000 earned the first US FDA approval for a therapeutic MR-guided focused-ultrasound device in 2004, for uterine fibroids.

Sources

Related